Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 83,792 shares at $32.06 ($2.7M) on 2021-01-11, disclosed to the SEC on 2021-01-12.
Seasonal sale ($2.7M) by Chairman, President & CEO — this insider has traded ITCI in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $31.64 | 4,585 | $145K | 5.4% |
| 2 | $31.64 | 4,585 | $145K | 5.4% |
| 3 | $32.06 | 37,311 | $1.2M | 44.6% |
| 4 | $32.06 | 37,311 | $1.2M | 44.6% |
| Total | $32.01 avg | 83,792 | $2.7M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |